EUVIMEDEUVIMED entdecken
Crossref

Identifying risk factors of anti‐TNF induced skin lesions and other adverse events in paediatric patients with inflammatory bowel disease

Karen van Hoeve, Debby Thomas, Tom Hillary, Ilse Hoffman, Erwin Dreesen

Journal of Pediatric Gastroenterology and Nutrition · 2024

DOI: 10.1002/jpn3.12066 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pediatric Gastroenterology and Nutrition, 2024. Verfasst von Karen van Hoeve und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paediatric gastroenterology & Hepatology & Nutrition, University Hospitals Leuven, KU Leuven, Leuven, Belgium. Hauptthemen laut MEDLINE: Inflammatory Bowel Diseases, Crohn Disease, Colitis, Ulcerative, Skin Diseases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: Mundipharma Comm. VA and Celltrion Healthcare Co., AbbVie, Almirall, Amgen, Janssen, Leo Pharma, Eli Lilly, Novartis, UCB Pharma, Janssen, R-Biopharm, and Prometheus.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

While higher infliximab (IFX) trough concentrations (TCs) are associated with better outcomes in patients with inflammatory bowel disease (IBD), they could pose a risk for adverse events (AEs), including IFX‐induced skin lesions. Therefore, we studied correlations between IFX TCs and occurrence of AEs in paediatric IBD patients.

Methods

In this single‐centre study, all children with Crohn's disease (CD) and ulcerative colitis (UC) receiving IFX maintenance therapy who underwent proactive drug monitoring between March 2015 and August 2022 were included. IFX doses/intervals/TCs and patient characteristics were systematically registered, as well as AEs and skin lesions appearance.

Results

A total of 109 patients (72 CD and 37 UC) contributed 2913 IFX TCs. During a median follow‐up of 3.0 [1.5–4.5] years, we observed 684 AEs in 101 patients and 49 skin lesions in 35 patients. There was no significant difference ( p = .467) in median TCs between patients with and without skin lesions. However, higher median IFX doses were associated with an increased hazard rate of skin lesions [HR 1.084 (1.024–1.148), p = .005], in addition to female sex [2.210 (1.187–5.310), p = .016] and diagnosis of CD [1.695 (1.241–1.877), p = .011]. Considering IFX therapeutic TC cut‐offs of 5.0 and 9.0 µg/mL, there was no significant difference in AE rate ( p = .749 and p = .833, respectively). Also, no significant association between IFX doses and AE rate ( p = .159).

Conclusions

Increasing the IFX dose to achieve therapeutic TCs may not increase the overall risk of AEs in paediatric IBD patients. However, concerns arise regarding the risk of skin lesions, especially in female CD patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Inflammatory Bowel DiseasesCrohn DiseaseColitis, UlcerativeSkin DiseasesHumansFemaleChildTumor Necrosis Factor InhibitorsGastrointestinal AgentsRemission InductionInfliximabRisk Factors

Stichwörter der Autor:innen

adverse eventschildinflammatory bowel diseaseinfliximabskin lesions

Substanzen

Tumor Necrosis Factor InhibitorsGastrointestinal AgentsInfliximab

Autor:innen und Institutionen

  • Department of Paediatric gastroenterology & Hepatology & Nutrition, University Hospitals Leuven, KU Leuven, Leuven, Belgium.
  • Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
  • Department of Dermatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.

Förderung

  • Mundipharma Comm. VA and Celltrion Healthcare Co.
  • AbbVie, Almirall, Amgen, Janssen, Leo Pharma, Eli Lilly, Novartis, UCB Pharma
  • Janssen, R-Biopharm, and Prometheus

Zitieren

APA

van Hoeve, K., Thomas, D., Hillary, T., Hoffman, I., & Dreesen, E. (2024). Identifying risk factors of anti‐TNF induced skin lesions and other adverse events in paediatric patients with inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition. https://doi.org/10.1002/jpn3.12066

Vancouver

van Hoeve K, Thomas D, Hillary T, Hoffman I, Dreesen E. Identifying risk factors of anti‐TNF induced skin lesions and other adverse events in paediatric patients with inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition. 2024. doi:10.1002/jpn3.12066

BibTeX
@article{vanHoeve2024,
  author = {van Hoeve, Karen and Thomas, Debby and Hillary, Tom and Hoffman, Ilse and Dreesen, Erwin},
  title = {Identifying risk factors of anti‐TNF induced skin lesions and other adverse events in paediatric patients with inflammatory bowel disease},
  journal = {Journal of Pediatric Gastroenterology and Nutrition},
  year = {2024},
  doi = {10.1002/jpn3.12066}
}
Kostenlos starten →